Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32 Metastatic Castration-resistant Prostate Cancer 3 Prostatic Diseases 2 Kidney Neoplasms 2 Carcinoma, Renal Cell 2 Urogenital Neoplasms 1 Thrombocytopenia 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer Metastatic 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Liver Neoplasms 1 High-Risk Localized Prostate Cancer 1 Glioma 1 Glioblastoma 1 Genital Neoplasms, Male 1 Genital Diseases, Male 1 Disease 1 Cytopenia 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Astrocytoma 1 Anemia 1

Interventions

Radiosurgery 79 Capecitabine 77 Oxaliplatin 74 Fluorouracil 69 Bevacizumab 69 Gemcitabine 67 Leucovorin 61 pembrolizumab 53 Nivolumab 53 Paclitaxel 48 Irinotecan 47 Radiotherapy 45 Cisplatin 44 Everolimus 38 Magnetic Resonance Spectroscopy 36 Drug Therapy 36 Docetaxel 36 Cyclophosphamide 35 Cetuximab 35 Ipilimumab 32 Carboplatin 32 Trastuzumab 31 Sunitinib 30 Sorafenib 26 Erlotinib Hydrochloride 25 Doxorubicin 23 Surveys and Questionnaires 20 Surgical Procedures, Operative 20 Specimen Handling 20 Biopsy 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasm Metastasis × Pluvicto × Clear all

NCT03392428 2022-06-13

TheraP

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡